Today I offer a brief glimpse of seven reports in the past six months on eye problems associated with - but not proven to be caused by - the use of GLP-1 drugs
1 ED symptoms can precede clinically evident CVD by up to 5 years, making it a valuable marker of subclinical CVD
This question concerns many patients prescribed glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda) for type 2 diabetes or weight management
Dangol M, Kim S, Li CG, Fakhraei Lahiji S, Jang M, Ma Y et al (2017) Anti-obesity effect of a novel caffeine-loaded dissolving microneedle patch in high-fat diet-induced obese C57BL/6J mice
While both peptides have been studied for tissue-regenerative properties, they appear to function through different mechanisms: BPC-157 may work primarily through growth factor-mediated pathways and nitric oxide systems
Sirtuins: Research advances on the therapeutic role in acute kidney injury